These are top 10 stocks traded on the Robinhood UK platform in July
DURHAM, N.C. - Micropep Technologies and Corteva, Inc. (NYSE: CTVA), a $50.6 billion agricultural technology company currently trading near its 52-week high, have formed a multi-year research and development collaboration to jointly develop peptide-based biocontrol solutions for crop protection, according to a press release issued Tuesday. According to InvestingPro data, Corteva maintains a strong financial health score, suggesting solid operational stability.
The partnership, established through Corteva’s Catalyst platform, will combine Micropep’s peptide technology with Corteva’s agricultural expertise to create new biofungicides and disease control products. Under the agreement, Corteva will receive exclusive global rights to apply specific peptides across biocontrol applications. The collaboration comes as Corteva demonstrates strong market performance, with a 44.6% total return over the past year.
This collaboration represents the first major industry validation of Micropep’s Krisalix discovery platform, which uses algorithms and bioassays to identify bioactive peptides for crop protection.
"This agreement with Corteva is a pivotal milestone in Micropep’s journey," said Mikael Courbot, CTO of Micropep. "It marks a new chapter in our mission to bring forward scalable, science-driven biological solutions for crop protection."
The companies aim to develop new crop protection tools that address resistance issues while providing environmentally friendly alternatives. The small peptides developed through this collaboration are designed to offer new modes of action with safety profiles suitable for agricultural applications.
Tom Greene, senior director at Corteva and global leader for Corteva Catalyst, said the partnership would allow the company to "advance sustainable agriculture in new ways" by leveraging their R&D capabilities alongside Micropep’s technology.
Corteva previously invested in Micropep through its Catalyst platform in 2024.
Micropep Technologies operates in both the US and France, focusing on micropeptide technology for agricultural applications. For investors seeking deeper insights into Corteva’s valuation and growth prospects, InvestingPro offers comprehensive analysis through its Pro Research Report, one of 1,400+ detailed company assessments available to subscribers.
In other recent news, Corteva Inc. has been the focus of several significant developments. The company has priced a $500 million public offering of Senior Notes through its subsidiary EIDP, Inc., with the proceeds intended for general corporate purposes, including the redemption of existing notes. Additionally, RBC Capital Markets has increased Corteva’s stock price target to $74, maintaining an Outperform rating, following the company’s strong first-quarter performance despite challenges such as foreign exchange headwinds and tariffs.
Jefferies has also raised its price target for Corteva to $92, citing the company’s growth potential and strategic initiatives. Meanwhile, BofA Securities adjusted Corteva’s price target to $73, emphasizing the company’s earnings growth and robust balance sheet, which supports investments in research and development. In another development, Turkey’s antitrust regulator has initiated an investigation into several seed market companies, including Corteva Turkey, over allegations of anti-competitive practices.
These recent developments highlight Corteva’s ongoing strategic initiatives and financial activities, as well as regulatory challenges in international markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.